SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients
SGLT2 inhibitor use in patients with type 2 diabetes was linked to a reduced risk of long COVID. These findings suggest potential therapeutic benefits beyond glycemic control and highlight the need for further investigation into SGLT2 inhibitors as part of post-COVID-19 management strategies.
Authors
- Chao-Bin Yeh
- Yu-Hsun Wang
- Yu-Hsiang Kuan
- Chung-Hsien Chaou
- Han-Wei Yeh
- Shun-Fa Yang
Institutions
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Virology Journal
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1186/s12985-025-03054-5
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29